![Katie Ellias](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Katie Ellias
Directeur/Membre du Conseil chez
SAB BIOTHERAPEUTICS, INC.
Profil
Katie Ellias is currently an Independent Director at SAB Biotherapeutics, Inc. since 2023.
Former roles include Managing Director at A Breakthrough T1D Venture LLC from 2018 to 2024, Director at Capillary Biomedical LLC from 2019 to 2022, Investment Director at Endeavour Vision SA from 2016 to 2017, Consultant at Tech Health Experts from 2017 to 2018, and Principal at Sofinnova Partners SAS from 2011 to 2016.
Also served as Director at Veralox Therapeutics, Inc., I2o Therapeutics, Inc., and DiogenX SAS. Education includes an undergraduate degree from Yale University in 2000 and an MBA from The Wharton School of the University of Pennsylvania in 2006.
Postes actifs de Katie Ellias
| Sociétés | Poste | Début |
|---|---|---|
| SAB BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 20/11/2023 |
Anciens postes connus de Katie Ellias
| Sociétés | Poste | Fin |
|---|---|---|
JDRF T1D Fund
 JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Private Equity Investor | 01/11/2024 |
Capillary Biomedical LLC
 Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management | Directeur/Membre du Conseil | 01/07/2022 |
Tech Health Experts
 Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services | Consultant / Advisor | 30/07/2018 |
Endeavour Vision SA
 Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Private Equity Investor | 30/09/2017 |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Private Equity Investor | 30/11/2016 |
Formation de Katie Ellias
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Capillary Biomedical LLC
Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management | Health Technology |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Finance |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
I2o Therapeutics, Inc.
 I2o Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops injection pills for biological therapies | Health Technology |
DiogenX SAS
 DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients | Health Technology |
Tech Health Experts
Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services | Technology Services |
SAB Biotherapeutics, Inc.
 SAB Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in advancing a new class of immunotherapies | Health Technology |
